Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota
Article first published online: 6 OCT 2007
Alimentary Pharmacology & Therapeutics
Volume 27, Issue 1, pages 48–57, January 2008
How to Cite
KAJANDER, K., MYLLYLUOMA, E., RAJILIĆ-STOJANOVIĆ, M., KYRÖNPALO, S., RASMUSSEN, M., JÄRVENPÄÄ, S., ZOETENDAL, E. G., DE VOS, W. M., VAPAATALO, H. and KORPELA, R. (2008), Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology & Therapeutics, 27: 48–57. doi: 10.1111/j.1365-2036.2007.03542.x
- Issue published online: 6 OCT 2007
- Article first published online: 6 OCT 2007
- Publication data Submitted 10 August 2007 First decision 5 September 2007 Resubmitted 14 September 2007 Accepted 24 September 2007
Background Irritable bowel syndrome is the most common diagnosis in gastroenterology. Trials suggest certain probiotics to be beneficial.
Aim To investigate the effects of multispecies probiotic supplementation (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium animalis ssp. lactis Bb12) on abdominal symptoms, quality of life, intestinal microbiota and inflammatory markers in irritable bowel syndrome.
Methods Eighty-six irritable bowel syndrome patients (Rome II criteria) participated in this randomized, placebo-controlled 5-month intervention. Patients were randomized to receive daily either multispecies probiotic supplementation or placebo. Irritable bowel syndrome symptoms, quality of life, microarray-based intestinal microbiota stability (n = 20), serum cytokines and sensitive C-reactive protein were monitored.
Results The composite irritable bowel syndrome score had at 5 months decreased 14 points (95% CI: −19 to −9) from baseline with the multispecies probiotic vs. three points (95% CI: −8 to 1) with placebo (P = 0.0083). Especially, distension and abdominal pain were affected. A stabilization of the microbiota was observed, as the microbiota similarity index increased with the probiotic supplementation (1.9 ± 3.1), while it decreased with placebo (−2.9 ± 1.7). No differences were seen in C-reactive protein.
Conclusions This multispecies probiotic seems to be an effective and safe option to alleviate symptoms of irritable bowel syndrome, and to stabilize the intestinal microbiota.